Insight

Johnson & Johnson Innovation aims for disruption

Johnson & Johnson Innovation aims for disruption

Johnson & Johnson Innovation, Boston, has high expectations for itself and its partners. "We're looking for ideas that will make a tremendous difference in patients' lives, not merely incremental progress," said Robert G. Urban, PhD, head of Johnson & Johnson Innovation, Boston. To do that, "we take advantage of the deep science emerging around us to develop bold platforms that make a big difference.

Patient-centric Baxalta capitalizes on Cambridge

Patient-centric Baxalta capitalizes on Cambridge


Jul 21, 2015

When Baxalta Incorporated spun out of Baxter on July 1, it already qualified as "big pharma." With USD 6 billion in annual revenues, 16,000 employees,...

Boehringer Ingelheim Pharmaceuticals:  “The world is our laboratory”

Boehringer Ingelheim Pharmaceuticals: “The world is our laboratory”


Jun 12, 2015

At Boehringer Ingelheim, “innovation is the element that defines us,” said Paola Casarosa, PhD, Corporate VP, Business Development and Licensing (BD&L)/Prescription Medicines. Its track record...

partnering360®: leverage and cultivate your dealmaker network

partnering360 is the network for dealmakers in the life science industry. This global community of more than 30,000 is constantly growing, and the partnering opportunities continually updating.